Rochester N.Y-The Canadian pharmaceutical company buying Bausch + Lomb is saying more about how it will operate once the deal closes.
In addition to leadership changes, Valeant Pharmaceutical says in letter to employee it plans to consolidate locations to streamline operations. It will headquarter its new U.S. Eye Health business unit in New Jersey at a combined Valeant/Bausch + Lomb location. Valeant will continue to operate all current manufacturing locations in the U.S., including Rochester, which it says is an important site given its manufacturing and R&D capabilities.
Valeant say it expects to save a total of $800 million, through next year without any reductions in the Bausch + Lomb North American field force or any material changes to the other field forces around the world.
Valeant says it expects remaining approvals for the deal to come in early August.